Mylan NV (MYL.OQ)
38.94USD
25 Apr 2018
$-1.31 (-3.25%)
$40.25
$40.08
$40.14
$38.45
1,860,873
1,742,700
$47.81
$29.44
Wed, Apr 25 2018
BRIEF-Mylan Adds To Growing Women's Healthcare Portfolio With Launch Of Generic For Oral Contraceptive Yaz
* MYLAN ADDS TO GROWING WOMEN'S HEALTHCARE PORTFOLIO WITH LAUNCH OF GENERIC FOR ORAL CONTRACEPTIVE YAZ®
EpiPen shortages seen in Canada, UK but U.S. supply intact
NEW YORK Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.
EpiPen shortages seen in Canada, UK but U.S. supply intact
NEW YORK, April 13 Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday.
Deals of the day-Mergers and acquisitions
April 13 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:
Mylan seeks deal for German Merck's consumer products unit: sources
FRANKFURT/NEW YORK Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said.
UPDATE 2-Mylan seeks deal for German Merck's consumer products unit -sources
FRANKFURT/NEW YORK, April 13 Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said.
Mylan seeks deal for German Merck’s consumer products unit -sources
FRANKFURT/NEW YORK, April 13 Generic drug maker Mylan is in advanced discussions to acquire Merck KGaA’s consumer health unit after other bidders failed to meet the German company’s price expectations, people familiar with the matter said.
BUZZ-India's Biocon rises; partner Mylan, FKB sign deal for drug in EU
** Biocon Ltd rises as much as 2.8 pct to 629.85 rupees, highest in over a month
BRIEF-Mylan Acquires Global Development & Marketing Rights For Meloxicam
* MYLAN - ACQUIRED GLOBAL DEVELOPMENT & MARKETING RIGHTS FROM PRAYOG LABS TO BRING TO MARKET FAST-ACTING MELOXICAM AS PROPOSED NON-NARCOTIC ANALGESIC
BRIEF-Mylan NV Says Reaffirming 2018 Guidance
* FY2018 EARNINGS PER SHARE VIEW $5.38, REVENUE VIEW $12.44 BILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:
- Teva Continues To Deliver But Analysts Stay Bearish
- Tesla Looking For The Ramp Up, Theresa May Looking For The Exit Ramp (Wall Street Breakfast Podcast)
- Wall Street Breakfast: Tesla Doubles Down On Model 3
- Allergan Seeks Dumb Money For Its Women's Health Unit
- Mylan (MYL) Investor Presentation - Slideshow
- Greenlight Capital's (David Einhorn) Q1 2018 Letter